Automate Your Wheel Strategy on TXG
With Tiblio's Option Bot, you can configure your own wheel strategy including TXG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TXG
- Rev/Share 5.0949
- Book/Share 5.7656
- PB 1.6529
- Debt/Equity 0.1133
- CurrentRatio 5.3728
- ROIC -0.2192
- MktCap 1189816707.0
- FreeCF/Share 0.3618
- PFCF 26.8194
- PE -7.4406
- Debt/Assets 0.0886
- DivYield 0
- ROE -0.2193
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | TXG | Leerink Partners | Outperform | Market Perform | $25 | $12 | Feb. 13, 2025 |
| Initiation | TXG | Leerink Partners | -- | Outperform | -- | $35 | Sept. 3, 2024 |
News
Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here's is How to Trade
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
10x Genomics, Inc. (NASDAQ:TXG ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Cassie Corneau – Senior Director, Investor Relations Serge Saxonov – Chief Executive Officer and Co-Founder Adam Taich – Chief Financial Officer Conference Call Participants Patrick Donnelly – Citi Kyle Mikson – Canaccord Genuity Madeline Mollman – Wolfe Research Matt Sykes – Goldman Sachs Kyle Boucher – TD Cowen Operator Ladies and gentlemen, thank you so much for standing by and welcome to 10x Genomics First Quarter 2025 Earnings Conference Call. Please note that this call is being recorded.
Read More
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
10x Genomics: Lower Cost Innovation May Drive A Rebound
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, particularly in the biopharma sector, presenting significant revenue opportunities. Despite historical underperformance and high risk, TXG's leading technologies and potential market penetration justify holding the stock at current price levels.
Read More
10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
10x Genomics, Inc. (NASDAQ:TXG ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Adam Taich - CFO Conference Call Participants Dan Brennan - TD Cowen Patrick Donnelly - Citi Dan Arias - Stifel Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Tejas Savant - Morgan Stanley Dan Leonard - UBS Subbu Nambi - Guggenheim Securities Kyle Mikson - Canaccord Genuity Luke Sergott - Barclays Matt Larew - William Blair Matt Sykes - Goldman Sachs …
Read More
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
About 10x Genomics, Inc. (TXG)
- IPO Date 2019-09-12
- Website https://www.10xgenomics.com
- Industry Medical - Healthcare Information Services
- CEO Dr. Serge Saxonov Ph.D.
- Employees 1306